OrthoPediatrics Corp. $KIDS Holdings Reduced by CenterBook Partners LP

CenterBook Partners LP lowered its stake in shares of OrthoPediatrics Corp. (NASDAQ:KIDS – Free Report) by 68.1% in the third quarter, HoldingsChannel reports. The fund owned 18,139 shares of the company’s stock after selling 38,756 shares during the quarter. CenterBook Partners LP’s holdings in OrthoPediatrics were worth $404,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. GAMMA Investing LLC lifted its holdings in shares of OrthoPediatrics by 70.3% during the 3rd quarter. GAMMA Investing LLC now owns 1,165 shares of the company’s stock worth $26,000 after acquiring an additional 481 shares during the period. Waverly Advisors LLC grew its holdings in OrthoPediatrics by 6.7% in the second quarter. Waverly Advisors LLC now owns 12,366 shares of the company’s stock valued at $237,000 after purchasing an additional 775 shares during the period. Legal & General Group Plc purchased a new stake in OrthoPediatrics in the second quarter valued at approximately $34,000. Quantinno Capital Management LP purchased a new stake in OrthoPediatrics in the first quarter valued at approximately $160,000. Finally, Conestoga Capital Advisors LLC increased its position in OrthoPediatrics by 16.2% during the third quarter. Conestoga Capital Advisors LLC now owns 74,975 shares of the company’s stock worth $1,670,000 after purchasing an additional 10,440 shares during the last quarter. 69.05% of the stock is currently owned by hedge funds and other institutional investors.

OrthoPediatrics Price Performance

NASDAQ KIDS opened at $32.58 on Friday. OrthoPediatrics Corp. has a 1-year low of $14.42 and a 1-year high of $34.53. The company has a quick ratio of 2.00, a current ratio of 4.55 and a debt-to-equity ratio of 0.29. The business’s 50-day simple moving average is $24.88 and its 200-day simple moving average is $20.23.

OrthoPediatrics (NASDAQ:KIDS – Get Free Report) last issued its earnings results on Tuesday, October 27th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.02). The firm had revenue of $72.66 million for the quarter, compared to analysts’ expectations of $68.50 million. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 12.83%. On average, research analysts anticipate that OrthoPediatrics Corp. will post -1.09 earnings per share for the current year.

Insider Activity at OrthoPediatrics

In other news, major shareholder Squadron Capital Llc sold 326,700 shares of the firm’s stock in a transaction on Friday, August 28th. The shares were sold at an average price of $23.04, for a total value of $7,527,168.00. Following the transaction, the insider owned 6,536,764 shares of the company’s stock, valued at approximately $150,607,042.56. This trade represents a 4.76% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, major shareholder Jennifer N. Pritzker sold 326,700 shares of OrthoPediatrics stock in a transaction on Friday, August 28th. The shares were sold at an average price of $23.04, for a total transaction of $7,527,168.00. Following the transaction, the insider owned 6,536,764 shares in the company, valued at $150,607,042.56. The trade was a 4.76% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 2,100,000 shares of company stock worth $46,747,931. Company insiders own 32.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. Canaccord Genuity Group increased their price target on shares of OrthoPediatrics from $28.00 to $30.00 and gave the stock a “buy” rating in a research note on Wednesday, October 28th. Stifel Nicolaus lifted their price target on shares of OrthoPediatrics from $24.00 to $27.00 and gave the company a “buy” rating in a report on Wednesday, October 28th. Truist Financial boosted their price objective on shares of OrthoPediatrics from $22.00 to $28.00 and gave the company a “hold” rating in a research note on Wednesday, October 28th. BTIG Research upped their price objective on OrthoPediatrics from $29.00 to $30.00 and gave the stock a “buy” rating in a report on Wednesday, October 28th. Finally, TD Cowen upped their price objective on OrthoPediatrics from $23.00 to $28.00 and gave the stock a “buy” rating in a report on Wednesday, October 28th. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $30.75.

Check Out Our Latest Research Report on KIDS

About OrthoPediatrics

(Free Report)

OrthoPediatrics Corp. develops and markets orthopedic implants and instruments designed specifically for children and adolescents. Its products support surgeons treating a range of pediatric conditions, including fractures, spinal deformities, limb-length differences and other orthopedic disorders. The company’s portfolio includes systems for trauma and deformity correction, scoliosis treatment, limb lengthening and external fixation, as well as specialized surgical instruments. It also provides related education and support for pediatric orthopedic surgeons and care teams.

Featured Stories

Want to see what other hedge funds are holding KIDS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OrthoPediatrics Corp. (NASDAQ:KIDS – Free Report).

Institutional Ownership by Quarter for OrthoPediatrics (NASDAQ:KIDS)

Receive News & Ratings for OrthoPediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OrthoPediatrics and related companies with MarketBeat.com's FREE daily email newsletter.